We hypothesized that the expression of a tumor antigen in the context of the oncolytic HSV-1 d106S may provoke CD8+ T cell responses against melanoma cells, combining oncolytic effects of the virus with enhanced expression of melanoma-associated antigens. The gene discussed is CD8A; the disease is melanoma.